MARKET

BIIB

BIIB

Biogen Inc
NASDAQ
291.90
-13.25
-4.34%
After Hours: 290.20 -1.7 -0.58% 19:58 11/28 EST
OPEN
296.03
PREV CLOSE
305.15
HIGH
303.11
LOW
290.31
VOLUME
2.08M
TURNOVER
0
52 WEEK HIGH
307.53
52 WEEK LOW
187.16
MARKET CAP
42.03B
P/E (TTM)
14.87
1D
5D
1M
3M
1Y
5Y
BRIEF-Eisai Shares Drop More Than 9% After A Report Of Death In Alzheimer's Drug Trial By Co And Biogen
Reuters · 20m ago
US STOCKS-Wall Street ends down sharply, hit by Apple and China worries
Reuters · 4h ago
What to know about the Alzheimer’s drug data coming out this week
Marketwatch.com · 4h ago
US STOCKS-Wall Street drops, weighed down by Apple and China worries
Reuters · 5h ago
US STOCKS-Apple, energy shares drag Wall St lower amid China COVID protests
Reuters · 7h ago
US STOCKS-Wall St losses limited as Amazon gains on upbeat Cyber Monday
Reuters · 9h ago
Axsome Hits The Stratosphere On Alzheimer's News As Biogen Faces A Setback
Axsome Therapeutics said its Alzheimer's treatment met the goals of a Phase 3 study, sending AXSM stock into the stratosphere.
Investor's Business Daily · 9h ago
Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall
Benzinga · 11h ago
More
About BIIB
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Webull offers kinds of Biogen Inc stock information, including NASDAQ:BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.